Healthcare has in the recent years gone through a process of digitalization and it has been driven by a speed in the innovation of the remote monitoring, artificial intelligence, and evidence-based digital treatment. Among these, Remote Therapeutic Monitoring (RTM), a subset of remote physiologic monitoring (RPM), has emerged as a powerful tool in chronic disease management and post‑acute care.
Compared to conventional RPM where the data gathered is a physiologic response i.e. blood pressure or glucose, RTM takes care beyond by measuring the patient reported outcome such as pain scale, treatment compliance, and medication utilization. Backed by positive shifts in policies, clinical validation, and ever more advanced online resources, RTM is beginning to bring around the aspect of continuous, proactive care that happens long after discharge or in between clinic visits.
Growth of Remote Patient Monitoring and RTM
It is estimated that the global market for RPM was USD 39.5 billion in the year 2023 and it is expected to increase almost two times to USD 77.9 in 2029 if the trend continues at a compound annual growth rate (CAGR) of almost 12 percent.
The remote therapeutic monitoring segment alone is estimated to be about USD 386.9 million in valuation in the U.S. alone, with future projections suggesting a CAGR of 17.2 percent between 2025 and 2030, and a U.S. market of RTM of USD 969.8 million by 2030.
It is estimated that over 71 million Americans, roughly 26 percent of the population, are expected to use some form of RPM by 2025, signaling broad consumer uptake.
Enabling Technologies and Integration
The latest RTM and RPM platforms have started utilizing wearable sensors, cellphones, and AI-driven analytics to gather, relay, and analyze ongoing health and patient reported data. These devices continuously transmit important vital functions, medication compliance, symptom monitoring, and mobility data to cellular or Wi-Fi networks to the cloud where it is available to clinical teams.
Advanced AI algorithms embedded in these systems can detect subtle signs of conditions like atrial fibrillation or heart failure exacerbation before symptoms present clinically. For example, FDA cleared platforms like Biofourmis use predictive analytics to reduce 30 day readmissions by up to 70 percent and cut overall care costs by approximately 38 percent.
Research published in 2025 also demonstrates deep learning architectures deployed over 5G networks achieving latency as low as 14.4 ms and prediction accuracy of 96.5 percent for vital sign monitoring in 1,000 patient clinical deployments.
A distinct use case today is patient centered AI apps for non‑healing wounds such as WoundAIssist released in 2025, which combines on device wound segmentation via deep learning with regular patient reported outcomes to enable ongoing clinician oversight and remote wound assessment.
Impact on Chronic Disease Management
In chronic disease management, the impact of RTM and RPM has been substantial. Studies have shown that Medicare patients in systems with higher telemedicine and RPM usage exhibit increased medication adherence for diabetes and hyperlipidemia, fewer emergency department visits, and more elective outpatient visits. In conditions such as hypertension and heart failure, RPM use is associated with significantly better control of blood pressure and hemoglobin A1c values in diabetes, along with reduced readmissions and hospital utilization.
One heart failure pilot study published in late 2024 combined both RPM and digital therapeutics to support continuous care, citing improved patient outcomes across the care continuum.
Virtual hospital models now leverage RTM and RPM for post acute care. Saudi Arabia’s Seha Virtual Hospital, the world’s largest virtual hospital, collaborates with 224 traditional hospitals offering 44 specialized services, all via remote monitoring and virtual consultation, delivering care continuity for chronic and post surgical patients in geographically remote areas.
The Role of Digital Therapeutics
Digital therapeutics (DTx) are software based, clinically validated treatments delivered via apps and platforms, often requiring rigorous clinical trials akin to pharmaceuticals.
Tools like Sleepio, delivering CBT for insomnia, have been recommended by NICE in the UK based on outcomes across trials showing symptom reduction in users.
In the U.S., emerging digital therapeutics cover conditions including type 2 diabetes, obesity, ADHD, hypertension, and mental health. Combining DTx with RTM creates a closed loop care model: symptom tracking and adherence reporting feed into digital therapy routines, enabling adaptive, personalized interventions.
Conclusion
Remote therapeutic monitoring is having a transformational effect, shifting to 24/7, data driven care that no longer requires a brick and mortar clinic. Markets are expanding robustly, technological sophistication, economic settlement and clinical approval are being aligned to assist in mainstream adoption.
Reductions in readmissions, improved medication compliance, and patient satisfaction are already improving chronic disease management and post acute recovery processes. Proactive intervention is not only being made possible, but increasingly regular, thanks to the injection of AI, wearables, conversational interface, and digital therapeutics.
As virtual hospitals, hospitals at home, and AI assisted wearables proliferate, the next chapter in care will be defined by seamless, personalized management of health, where continuous monitoring and therapy happen in the home, in real time, and in partnership with the patient.